AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34231956 — intervention group
Group type: COMPARATOR
Intervention: All techniques (Conventional freehand, Dynamic CAIS, Static CAIS)
Number of subjects: 90
Study 32184121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 40 mg/m2 plus radiation therapy (RT)
Number of subjects: 70
Study 32184121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) 250 mg/m2 plus a loading dose of 400 mg/m2 plus radiation therapy (RT)
Number of subjects: 70
Study 32184121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) in HPV+ oropharyngeal carcinoma
Number of subjects: 70
Study 32184121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) in HPV- oropharyngeal carcinoma
Number of subjects: 70
Study 35076737 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic fundoplication (RALF)
Number of subjects: 40
Study 35076737 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic fundoplication (CLF)
Number of subjects: 40
Study 33000390 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support alert for anticoagulation prescription
Number of subjects: 248
Study 33000390 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients categorized as high-risk for bleeding
Number of subjects: 248
Study 33715238 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention (BI)
Number of subjects: 61
Study 33715238 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled Water Station (CWS)
Number of subjects: 61
Study 33715238 — intervention group
Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 61
Study 34039236 — intervention group
Group type: EXPERIMENTAL
Intervention: My Food & Mood m‐Health program for 8 weeks
Number of subjects: 0
Study 33061398 — intervention group
Group type: COMPARATOR
Intervention: Low-dose simvastatin (≤20 mg/day)
Number of subjects: 125
Study 33061398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (40 mg/day for 6 weeks, then 80 mg/day for 6 weeks)
Number of subjects: 125
Study 35688116 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology group (tablet use)
Number of subjects: 70
Study 35688116 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (toys use)
Number of subjects: 70
Study 34418221 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH) program
Number of subjects: 63
Study 34418221 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group with positive expectation induction
Number of subjects: 63
Study 34418221 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group without positive expectation induction
Number of subjects: 63
Study 32179393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB) with 25 ml of 0.5% ropivacaine
Number of subjects: 0
Study 32179393 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 0
Study 33395690 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental treatments with diverse microbial communities
Number of subjects: 12
Study 33395690 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental perturbations
Number of subjects: 12
Study 34665507 — intervention group
Group type: EXPERIMENTAL
Intervention: micellar curcumin
Number of subjects: 12
Study 34665507 — intervention group
Group type: EXPERIMENTAL
Intervention: curcumin-γ-cyclodextrin complex
Number of subjects: 12
Study 34665507 — intervention group
Group type: COMPARATOR
Intervention: all other formulations
Number of subjects: 12
Study 35320215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate in zero-calorie soft drink (Group B)
Number of subjects: 162
Study 35320215 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate in water (Group A)
Number of subjects: 162
Study 32134129 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (RBC top-up transfusion to 12 g/dL)
Number of subjects: 67
Study 32134129 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (no RBCs)
Number of subjects: 67
Study 33412339 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnoy's solution applied for 5 minutes after surgical excision
Number of subjects: 40
Study 33412339 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision without Carnoy's solution
Number of subjects: 40
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl for 30 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl for 60 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl + PUI for 30 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl + PUI for 60 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl for 30 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl for 60 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + PUI for 30 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + PUI for 60 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: COMPARATOR
Intervention: Distilled water for 30 min
Number of subjects: 60
Study 33314440 — intervention group
Group type: COMPARATOR
Intervention: Distilled water for 60 min
Number of subjects: 60
Study 35857811 — intervention group
Group type: EXPERIMENTAL
Intervention: Switchers (those who switched to the other antipsychotic)
Number of subjects: 327
Study 35857811 — intervention group
Group type: COMPARATOR
Intervention: Stayers (those who remained on the same compound)
Number of subjects: 327
Study 33617999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 395
Study 33617999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 33617999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatological consultation
Number of subjects: 395
Study 33617999 — intervention group
Group type: COMPARATOR
Intervention: No dermatological consultation
Number of subjects: 395
Study 32539907 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM-PLUS
Number of subjects: 161
Study 32539907 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 161
Study 35998768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (standardized protocol)
Number of subjects: 160
Study 35998768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 32873964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific genetic variants for testosterone
Number of subjects: 337199
Study 32873964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific variants as genetic instruments for Mendelian randomization
Number of subjects: 337199
Study 32873964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific polygenic risk score models for testosterone
Number of subjects: 337199
Study 32441987 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudge survey
Number of subjects: 182
Study 32441987 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent
Number of subjects: 182
Study 36001509 — intervention group
Group type: EXPERIMENTAL
Intervention: SA‐MI Training (tactile stimulation applied to the left or right wrist during MI tasks)
Number of subjects: 26
Study 36001509 — intervention group
Group type: COMPARATOR
Intervention: Control-Group (pure MI tasks without tactile sensation assistance)
Number of subjects: 26
Study 36001509 — intervention group
Group type: EXPERIMENTAL
Intervention: SA‐MI Training
Number of subjects: 26
Study 36001509 — intervention group
Group type: COMPARATOR
Intervention: Control-Group
Number of subjects: 26
Study 34488851 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a registry for RCTs
Number of subjects: 87
Study 34488851 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding data storage in a registry
Number of subjects: 87
Study 34488851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing participation
Number of subjects: 87
Study 34488851 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of GP in decision-making
Number of subjects: 87
Study 35906015 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive messages focusing on vaccine safety
Number of subjects: 5784
Study 35906015 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 5784
Study 35906015 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attribute frames, risky choice frames, and priming descriptive norms messages
Number of subjects: 5784
Study 33502090 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10, 25 mg)
Number of subjects: 6959
Study 33502090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6959
Study 33502090 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvascular disease with kidney dysfunction
Number of subjects: 6959
Study 34060003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lookware™ (video game-based digital therapeutic)
Number of subjects: 54
Study 34060003 — intervention group
Group type: COMPARATOR
Intervention: Control video game
Number of subjects: 54
Study 34948744 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) warm-up, performed 2 to 3 times a week for 20 weeks.
Number of subjects: 1409
Study 34948744 — intervention group
Group type: COMPARATOR
Intervention: High team adherence to NMT warm-up (n = 17 teams).
Number of subjects: 1409
Study 34948744 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy analysis of NMT warm-up (n = 7 teams).
Number of subjects: 1409
Study 34260836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily)
Number of subjects: 329
Study 34260836 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (investigator's choice from 10 options)
Number of subjects: 329
Study 32051317 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP) injection
Number of subjects: 240
Study 32051317 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 240
Study 36115392 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Blalock Taussig Thomas shunt (mBTTS)
Number of subjects: 0
Study 36115392 — intervention group
Group type: COMPARATOR
Intervention: right‐ventricular‐to‐pulmonary‐artery shunt (RVPAS)
Number of subjects: 0
Study 36350712 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist palliative care intervention (four protocolized quarterly visits with a PC nurse practitioner)
Number of subjects: 50
Study 36350712 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 33782244 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital nerve block (DNB) performed on the second and third PIPs of the dominant hand
Number of subjects: 83
Study 33782244 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection in the same level at the control side)
Number of subjects: 83
Study 34843323 — intervention group
Group type: EXPERIMENTAL
Intervention: GenerationPMTO intervention
Number of subjects: 153
Study 33857943 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Homeopathy (IH)
Number of subjects: 60
Study 33857943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-Control Reminder Script (PCRS)
Number of subjects: 137
Study 33244149 — intervention group
Group type: COMPARATOR
Intervention: No PCRS (Control)
Number of subjects: 137
Study 33244149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (both groups)
Number of subjects: 137
Study 36050695 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)
Number of subjects: 44
Study 36050695 — intervention group
Group type: COMPARATOR
Intervention: 4 g/day olive oil (placebo)
Number of subjects: 44
Study 33386187 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention
Number of subjects: 265
Study 33386187 — intervention group
Group type: COMPARATOR
Intervention: Standard consent (Control)
Number of subjects: 265
Study 36087395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg (LAN)
Number of subjects: 53
Study 36087395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 53
Study 33978350 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA + L-Arg (3g) + Mg (350 mg) + Sal (100 mg)
Number of subjects: 79
Study 33978350 — intervention group
Group type: COMPARATOR
Intervention: LDA
Number of subjects: 79
Study 35512154 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld image-free robotic system (robot group)
Number of subjects: 147
Study 35512154 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (conventional group)
Number of subjects: 147
Study 35512154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 32911433 — intervention group
Group type: EXPERIMENTAL
Intervention: Early venoarterial extracorporeal membrane oxygenation–facilitated resuscitation for circulatory support and percutaneous coronary intervention, when needed.
Number of subjects: 174
Study 32911433 — intervention group
Group type: COMPARATOR
Intervention: Standard advanced cardiac life support resuscitation.
Number of subjects: 174
Study 35586025 — intervention group
Group type: EXPERIMENTAL
Intervention: MedSafer intervention (personalized deprescribing reports)
Number of subjects: 140
Study 35586025 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medication reconciliation)
Number of subjects: 140
Study 35586025 — intervention group
Group type: EXPERIMENTAL
Intervention: MedSafer intervention
Number of subjects: 140
Study 35586025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 33262253 — intervention group
Group type: EXPERIMENTAL
Intervention: Real taVNS
Number of subjects: 70
Study 33262253 — intervention group
Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 70
Study 34244279 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (LT) delivered via a portable device, daily for 30 min at medium intensity for 8 weeks
Number of subjects: 50
Study 36154518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL) therapy at 10,000 lux, applied daily between the second and eighth days of chemotherapy
Number of subjects: 72
Study 36154518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BWL therapy)
Number of subjects: 72
Study 36154518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL) therapy
Number of subjects: 72
Study 33916497 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated peripheral intravenous replacement (CIPIR)
Number of subjects: 283
Study 33916497 — intervention group
Group type: COMPARATOR
Intervention: Usual care with routine PVC replacement every three days (Control)
Number of subjects: 283
Study 33951362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenous)
Number of subjects: 8880
Study 33951362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8880
Study 34427681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening with low-dose computed tomography (LDCT)
Number of subjects: 53452
Study 34427681 — intervention group
Group type: COMPARATOR
Intervention: Chest radiograph screening
Number of subjects: 53452
Study 32439422 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning training programme
Number of subjects: 29
Study 35743349 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin sealant
Number of subjects: 62
Study 35743349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled resin sealant
Number of subjects: 62
Study 36130174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive-behavioral stress management intervention
Number of subjects: 102
Study 33232588 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 333
Study 33232588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 32745092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81-mg twice daily
Number of subjects: 329
Study 32745092 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin 30-mg twice daily
Number of subjects: 329
Study 32745092 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 329
Study 36351943 — intervention group
Group type: EXPERIMENTAL
Intervention: Device method
Number of subjects: 28
Study 36351943 — intervention group
Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 28
Study 33938709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Vitamin D3 injection
Number of subjects: 40
Study 33938709 — intervention group
Group type: COMPARATOR
Intervention: Intralesional Candida Albicans Antigen injection
Number of subjects: 40
Study 32475159 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS‐TC
Number of subjects: 6024
Study 32475159 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6024
Study 34257407 — intervention group
Group type: EXPERIMENTAL
Intervention: Primeiros Laços (intervention group, n=40)
Number of subjects: 80
Study 34257407 — intervention group
Group type: COMPARATOR
Intervention: Healthcare as usual (control group, n=40)
Number of subjects: 80
Study 33170239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 2157
Study 33170239 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3s (1 g/d)
Number of subjects: 2157
Study 33170239 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-training exercise program
Number of subjects: 2157
Study 33170239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2157
Study 36070045 — intervention group
Group type: EXPERIMENTAL
Intervention: At Home/Chez Soi dataset
Number of subjects: 2
Study 36070045 — intervention group
Group type: EXPERIMENTAL
Intervention: Without A Home dataset
Number of subjects: 2
Study 33860587 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis plus Hyoscyamus niger L. methanolic extract syrup (1.6 mg of extract and 450 mg of propolis per 10 mL, administered three times a day for 6 days)
Number of subjects: 50
Study 33860587 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 50
Study 32279123 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic visual training (SVT)
Number of subjects: 26
Study 32279123 — intervention group
Group type: COMPARATOR
Intervention: Control training (similar exercises without lenses)
Number of subjects: 26
Study 35996188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 739
Study 35996188 — intervention group
Group type: COMPARATOR
Intervention: No TEAS treatment (Control)
Number of subjects: 739
Study 33506373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive toilet training program
Number of subjects: 4
Study 34061314 — intervention group
Group type: EXPERIMENTAL
Intervention: Centhaquine (0.01 mg/kg) administered in 100 mL of normal saline infusion over 1 h
Number of subjects: 105
Study 34061314 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study 32965539 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day ART (ART-123: day 1, placebo: days 2–3)
Number of subjects: 79
Study 32965539 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day ART (ART-123: days 1–3)
Number of subjects: 79
Study 32965539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 1–3)
Number of subjects: 79
Study 34788569 — intervention group
Group type: EXPERIMENTAL
Intervention: UC + 12-week program of exercise and education (PREVENT)
Number of subjects: 184
Study 34788569 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 184
Study 34314400 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plate fixation
Number of subjects: 0
Study 34314400 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast immobilization
Number of subjects: 0
Study 35809289 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-abortion care (PAC)
Number of subjects: 72
Study 35809289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAC)
Number of subjects: 72
Study 32508141 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency information (yes)
Number of subjects: 467
Study 32508141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal (yes)
Number of subjects: 467
Study 32508141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of contingency information and fear appeal
Number of subjects: 467
Study 32508141 — intervention group
Group type: COMPARATOR
Intervention: Control condition (irrelevant information)
Number of subjects: 467
Study 37853408 — intervention group
Group type: COMPARATOR
Intervention: SMC + Vitamin A + PlumpyDoz (SMC-APd)
Number of subjects: 1059
Study 37853408 — intervention group
Group type: COMPARATOR
Intervention: SMC + Vitamin A + Zinc (SMC-AZc)
Number of subjects: 1059
Study 37853408 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1059
Study 33404689 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 571
Study 32084035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking
Number of subjects: 9
Study 32084035 — intervention group
Group type: COMPARATOR
Intervention: Unassisted overground walking
Number of subjects: 9
Study 34224785 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula with synbiotics (AAF-S)
Number of subjects: 169
Study 34224785 — intervention group
Group type: COMPARATOR
Intervention: Amino acid-based formula (AAF)
Number of subjects: 169
Study 34034748 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial triglyceride (PTG) concentration during oral fat tolerance testing (OFTT)
Number of subjects: 472
Study 34034748 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 472
Study 33380521 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 9
Study 33380521 — intervention group
Group type: COMPARATOR
Intervention: Lanraplenib
Number of subjects: 9